Updates in the Management of Relapsed and Refractory Acute Lymphoblastic Leukemia: An Urgent Plea for New Treatments Is Being Answered!
Adam S. DuVall, Jori Sheade, Daniela Anderson, Samuel J. Yates, Wendy Stock
Abstract
The treatment of acute lymphoblastic leukemia (ALL) has dramatically changed over the past three decades. However, relapsed and/or refractory ALL still remains with a very low survival and high morbidity associated with its treatment. Here, we will review the outstanding progress that has been made in the treatment of relapsed and/or refractory ALL and discuss future directions and challenges that require further investigation.
Topics & Concepts
MedicineRefractory (planetary science)Intensive care medicinePleaLymphoblastic LeukemiaAcute lymphocytic leukemiaMEDLINEPediatricsLeukemiaAcute leukemiaAcute Lymphoblastic Leukemia researchChronic Myeloid Leukemia TreatmentsAcute Myeloid Leukemia Research